Messing with HIV

Sangamo Biosciences is putting a different spin on gene therapy. 

Jef Akst
Jef Akst

Jef Akst is managing editor of The Scientist, where she started as an intern in 2009 after receiving a master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses.

View full profile.


Learn about our editorial policies.

Jun 1, 2012

Infographic: Messing with HIV
View full size JPG | PDF
LUCY READING-IKKANDA

Sangamo Biosciences is putting a different spin on gene therapy. Rather than replace or supplement a mutated gene with an accurate copy, Sangamo researchers are introducing a mutant copy of the gene for the HIV co-receptor CCR5 into the T cells of HIV patients. This prevents the expression of CCR5 on the cell’s surface, and thus inhibits HIV from infecting cells.

Read the full story.

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?